Fiche publication
Date publication
mars 2019
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials, golimumab showed efficacy as induction and maintenance therapy in anti-TNF naïve UC patients. However, confirmatory data on effectiveness in the real world setting are needed.
Mots clés
Effectiveness, Golimumab, Persistence, Real-world evidence, Ulcerative colitis
Référence
Dig Liver Dis. 2019 03;51(3):327-334
